ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2015
Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04016571 (Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2024Pooled it
- Autogenic drainage for airway clearance in cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Autogenic drainage for airway clearance in cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.The American journal of clinical nutrition · 2019Trial
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Trial
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Role of inhaled antibiotics in the era of highly effective CFTR modulators.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells.Frontiers in immunology · 2023Article
- A new path for CF clinical trials through the use of historical controls.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Article
- Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.BMJ open respiratory research · 2021Article
- The effects of the addition of a new airway clearance device to chest physiotherapy in children with cystic fibrosis pulmonary exacerbations.Journal of mother and child · 2021Article
- Acute Pulmonary Exacerbations in Cystic Fibrosis.Seminars in respiratory and critical care medicine · 2019Review
- Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.Journal of managed care & specialty pharmacy · 2019Observational
- Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis.Pediatric pulmonology · 2018Observational
- Antibiotic duration and changes in FEVBMC pulmonary medicine · 2017Article
- Poor recovery from a pulmonary exacerbation does not lead to accelerated FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017Article
- Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016Article
- C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.Journal of pulmonary & respiratory medicine · 2016Article
- Background and Epidemiology.Pediatric clinics of North America · 2016Review
- IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
backgroundPulmonary exacerbations (PEx) are important CF clinical events.
methodsWe studied time to next PEx following intravenous (IV) antibiotic PEx treatment among Cleveland Ohio CF center patients occurring between January 2010 and September 2014. Patient demographics, clinical presentations, and treatments were modeled by Cox proportional hazards regression to identify covariates associated with time to next PEx.
results193 patients were treated for PEx; 155 had a subsequent IV-treated PEx. Six covariates were associated with future PEx hazard: number of PEx in the prior year (hazard ratio 25.1 for ≥3 and 4.4 for 1-2 prior-year PEx versus none; P<.0001), IV treatment duration in weeks (1.2; P=.0004), percent hospital treatment (1.1; P=.0018), and chronic inhaled aminoglycosides (2.5; P<.0001), leukotriene modifiers (1.8; P=.0031), and high dose ibuprofen (0.52; P=.0006).
conclusionsTime to next PEx was profoundly associated with prior-year PEx, suggestive of high-risk PEx phenotypes that warrant recognition and further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.